Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
 
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and Disease    2017, Vol. 8 Issue (5) : 519-530     DOI: 10.14336/AD.2017.0710
Original Article |
Aging Systemic Milieu Impairs Outcome after Ischemic Stroke in Rats
Mengxiong Pan1,2,Peng Wang1,Chengcai Zheng1,Hongxia Zhang2,Siyang Lin1,Bei Shao1,Qichuan Zhuge1,Kunlin Jin1,2,*
1Zhejiang Provincial Key Laboratory of Aging and Neurological Disorder Research, the First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China
2Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA
Download: PDF(1568 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    
Abstract  

Compelling evidence indicates that factors in the blood can profoundly reverse aging-related impairments, as exposure of aged mice to young blood rejuvenates adult stem cell function, improves cognition, and ameliorates cardiac hypertrophy. Systemic factors from mice can also extend the life span of a partner exposed to a lethal treatment or disease. These findings suggest that the systemic milieu of a healthy young partner may be beneficial for an aged organism. However, it is unknown whether a healthy young systemic milieu can improve functional recovery after ischemic stroke. Intraperitoneal administration of young plasma into aged rats after ischemic stroke induced by distal middle cerebral artery occlusion (dMCAO) reduced infarct volume and motor impairment, compared with vehicle group. On the contrary, intraperitoneal administration of plasma from aged rats into young ischemic rats worsened brain injury and motor deficits. Using a proteomic approach, we found that haptoglobin levels were significantly increased in serum of aged rats and that intraperitoneal administration of haptoglobin impaired outcome after ischemic stroke in young rats. Our data suggest that the aging systemic milieu plays a critical role in functional outcome after ischemic stroke.

Keywords ischemic stroke      systemic milieu      outcome      plasma      haptoglobin     
Corresponding Authors: Kunlin Jin   
Just Accepted Date: 04 August 2017   Issue Date: 26 September 2017
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Mengxiong Pan
Peng Wang
Chengcai Zheng
Hongxia Zhang
Siyang Lin
Bei Shao
Qichuan Zhuge
Kunlin Jin
Cite this article:   
Mengxiong Pan,Peng Wang,Chengcai Zheng, et al. Aging Systemic Milieu Impairs Outcome after Ischemic Stroke in Rats[J]. A&D, 2017, 8(5): 519-530.
URL:  
http://www.aginganddisease.org/EN/10.14336/AD.2017.0710     OR     http://www.aginganddisease.org/EN/Y2017/V8/I5/519
Figure 1.  Administration of old plasma into young ischemic rats worsensyoungyoungwrosew were outcomeafter ischemic stroke

(A) Schematic illustrating intraperitonealinjection of young (2-month-old) or old (22-month-old) plasma into young ischemic rats 1 hr after onset of ischemia, twice per day for 3 days. (B) Infarct areas (white) in TTC-(red) stained coronal brain section from vehicle, young and old plasma-treated rats at 3 days after stroke. (C) Quantitative analysis of infarct volume in vehicle, young and old plasma-treated rats at 3 days after ischemic stroke. (D) Motor function deficits of young ischemic rats were assessed by beam balance test, EBST and sticky tape test on the 1st and 3rd day after administration with vehicle, young, or old rat plasma. Values presented as mean ± SEM. *P<0.05; **P<0.01, compared with vehicle-treated group. N=7-12 per group.

Figure 2.  Young plasma reduces youngyounginfarct volume and improves neurobehavioral deficits in aged ischemic rats after stroke

(A) Schematic illustrating intraperitonealinjection of young (2-month-old) or old (22-month-old) plasma into aged ischemic rats 1 hr after onset of ischemia. (B) Representative images of TTC staining in cerebral sections of vehicle, young and old plasma-treated group, twice per day for 3 days after stroke. (C) Infarct volume (expressed as percentage whole brain volume) in vehicle, young and old plasma-treated aged rats 3 days after stroke. (D) Neurobehavioral tests includingbeam balance test, EBST and sticky tape test were performedon the 1st and 3rd day after injection with vehicle, young, or old rat plasma into aged rats. Values presented as mean ± SEM. *P<0.05, compared with vehicle-treated group. N=7-12 per group.

Figure 3.  Old plasma administration inhibits long-term recovery after experimental stroke in young ischemic rats

(A) Representative images of lesion volume at low magnification view (top panel) and H&E-stained coronal brain sections (bottom panel) in vehicle, young plasma and old plasma-treated young rats 15 days after stroke. (B) Quantitative analysis of infarct volume in vehicle, young and old plasma-treated young rats 15 days after ischemic stroke. (C) Sticky tape test scores in young rats at 1, 3, 7 and 15 days after treatment with vehicle, young plasma and old plasma. (D) Quantitative analysis of infarct volume in vehicle, young and old plasma-treated aged rats 15 days after ischemic stroke. (E) Sticky tape test scores in aged rats at 1, 3, 7 and 15 days after treatment with vehicle, young plasma and old plasma. Values presented as mean ± SEM. *P < 0.05; **P < 0.01, compared with vehicle-treated group. N=7-12 per group.

Figure 4.  Differentially expressed proteins identified from the 2D-DIGE profiling of young and old plasma of human and rat

(A) Protein from rat young plasma was labeled with Cy3 (green), protein from rat old plasma was labeled with Cy5 (red), and samples were mixed prior to 2-dimensional PAGE (horizontal axis, pI; vertical axis, Mr). (B) Cy3 (green) was used to label young human plasma and Cy5 was used to label old human plasma. N=10/group. (C) Venn diagram of differentially expressed protein spots identified from the 2D-DIGE profiling of young and old human (red) and rat plasma (grey). In the brown intersection are shown four factors changed in both proteomic screens.

Figure 5.  Circulation level of haptoglobin is significantly increased in both old rat and human plasma

(A) DeCyder Analysis shows the location of a 2D-DIGE gel with yellow line pointing to protein spots, identified as haptoglobin, that was differentially expressed across age, >72.5 change in abundance. (B) 3-D view simulation of a close-up of the region of 2D-DIGE gel image, and the associated graph of representative up-regulated haptoglobin during aging. (C) ELISA shows that haptoglobin was increased in young and old rat plasma. N=7 rats per group. (D) ELISA shows that haptoglobin concentration in the plasma of 20-, 40-, and 80-years-old human subjects. (E) Western blot analysis confirms that increased level of haptoglobin α1, α2 and β in old human plasma. (F and G) Relative optical intensity of haptoglobin β and α2. Data were from 10 per group. Values were presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

Figure 6.  Systemic exposure to haptoglobin increases infarct volume and deteriorates neurobehavioral deficits in young ischemic rats

(A) Schematic of young rats injected intraperitoneally with haptoglobin (0.5 g/L in 150 µl) or vehicle 1 hr after ischemic stroke. (B) Representative images of TTC staining in coronal brain sections of vehicle- or haptoglobin-treated young ischemic rats. (C) Quantitative analysis of infarct volume in vehicle- and haptoglobin-treated young rats 3 days after ischemic stroke. (C) Neurobehavioral deficitswere determined by beam balance test, EBST and corner test in young ischemic rats after injection with vehicle or haptoglobin. Values presented as mean ± SEM. *P< 0.05, **P< 0.01. N=7-12 per group.

Figure 7.  Systemic exposure to haptoglobin affect infarct volume and neurobehavioral deficits in aged ischemic rats

(A) Schematic of aged rats injected intraperitoneally with haptoglobin (0.5 g/L in 150 µl) or vehicle 1 hr after ischemic stroke. (B) Representative images of TTC staining in coronal brain sections of vehicle- or haptoglobin-treated aged ischemic rats. (C) Quantitative analysis of infarct volume in vehicle- and haptoglobin-treated aged rats 3 days after ischemic stroke. (C) Neurobehavioral deficits were determined by beam balance test, EBST and corner test in aged ischemic rats after injection with vehicle or haptoglobin. Values presented as mean ± SEM. N=8-14 per group.

[1] Ramirez-Lassepas M (1998). Stroke and the aging of the brain and the arteries. Geriatrics, 53: S44-48.
[2] Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, et al. (2014). Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med, 20: 659-663
http://dx.doi.org/10.1038/nm.3569
[3] Loffredo FS, Steinhauser ML, Jay SM, Gannon J, Pancoast JR, Yalamanchi P, et al. (2013). Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell, 153: 828-839
http://118.145.16.217/magsci/article/article?id=19669918
[4] Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature, 433: 760-764
http://dx.doi.org/10.1038/nature03260
[5] Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, et al. (2007). Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science, 317: 807-810
http://dx.doi.org/10.1126/science.1144090
[6] Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, et al. (2011). The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 477: 90-94
http://dx.doi.org/10.1038/nature10357
[7] Conboy MJ, Conboy IM, Rando TA (2013). Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity. Aging Cell, 12: 525-530
http://118.145.16.217/magsci/article/article?id=19266310
[8] Nawashiro H, Martin D, Hallenbeck JM (1997). Inhibition of tumor necrosis factor and amelioration of brain infarction in mice. J Cereb Blood Flow Metab, 17: 229-232
http://dx.doi.org/10.1097/00004647-199702000-00013
[9] Won SJ, Xie L, Kim SH, Tang H, Wang Y, Mao X, et al. (2006). Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke. Brain Res, 1123: 237-244
http://dx.doi.org/10.1016/j.brainres.2006.09.055
[10] Pang C, Cao L, Wu F, Wang L, Wang G, Yu Y, et al. (2015). The effect of trans-resveratrol on post-stroke depression via regulation of hypothalamus-pituitary-adrenal axis. Neuropharmacology, 97: 447-456
http://dx.doi.org/10.1016/j.neuropharm.2015.04.017
[11] Wang LQ, Lin ZZ, Zhang HX, Shao B, Xiao L, Jiang HG, et al. (2014). Timing and dose regimens of marrow mesenchymal stem cell transplantation affect the outcomes and neuroinflammatory response after ischemic stroke. CNS Neurosci Ther, 20: 317-326
http://118.145.16.217/magsci/article/article?id=18841566
[12] Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR (1990). A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab, 10: 290-293
http://dx.doi.org/10.1038/jcbfm.1990.47
[13] Wang X, Mao X, Xie L, Greenberg DA, Jin K (2009). Involvement of Notch1 signaling in neurogenesis in the subventricular zone of normal and ischemic rat brain in vivo. J Cereb Blood Flow Metab, 29: 1644-1654
http://dx.doi.org/10.1038/jcbfm.2009.83
[14] Ohlsson AL, Johansson BB (1995). Environment influences functional outcome of cerebral infarction in rats. Stroke, 26: 644-649
http://dx.doi.org/10.1161/01.STR.26.4.644
[15] Bu Y, Kwon S, Kim YT, Kim MY, Choi H, Kim JG, et al. (2010). Neuroprotective effect of HT008-1, a prescription of traditional Korean medicine, on transient focal cerebral ischemia model in rats. Phytother Res, 24: 1207-1212
http://dx.doi.org/10.1002/ptr.2908
[16] Puurunen K, Jolkkonen J, Sirvio J, Haapalinna A, Sivenius J (2001). An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology, 40: 597-606
http://dx.doi.org/10.1016/S0028-3908(00)00182-9
[17] Hoyman L, Weese GD, Frommer GP (1979). Tactile discrimination performance deficits following neglect-producing unilateral lateral hypothalamic lesions in the rat. Physiol Behav, 22: 139-147
http://dx.doi.org/10.1016/0031-9384(79)90415-3
[18] Schallert T, Whishaw IQ (1984). Bilateral cutaneous stimulation of the somatosensory system in hemidecorticate rats. Behav Neurosci, 98: 518-540
http://dx.doi.org/10.1037/0735-7044.98.3.518
[19] d’Avila JC, Lam TI, Bingham D, Shi J, Won SJ, Kauppinen TM, et al. (2012). Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. Journal of neuroinflammation, 9: 31
[20] Schallert T, Upchurch M, Wilcox RE, Vaughn DM (1983). Posture-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum. Pharmacol Biochem Behav, 18: 753-759
http://dx.doi.org/10.1016/0091-3057(83)90019-9
[21] Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G (2002). Behavioral tests after intracerebral hemorrhage in the rat. Stroke, 33: 2478-2484
http://dx.doi.org/10.1161/01.STR.0000032302.91894.0F
[22] Zhang L, Schallert T, Zhang ZG, Jiang Q, Arniego P, Li Q, et al. (2002). A test for detecting long-term sensorimotor dysfunction in the mouse after focal cerebral ischemia. J Neurosci Methods, 117: 207-214
http://dx.doi.org/10.1016/S0165-0270(02)00114-0
[23] Spagnuolo MS, Maresca B, Mollica MP, Cavaliere G, Cefaliello C, Trinchese G, et al. (2014). Haptoglobin increases with age in rat hippocampus and modulates Apolipoprotein E mediated cholesterol trafficking in neuroblastoma cell lines. Front Cell Neurosci, 8: 212
[24] Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G (2009). Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Ann Med, 41: 522-532
http://dx.doi.org/10.1080/07853890903089453
[25] Brea D, Sobrino T, Blanco M, Fraga M, Agulla J, Rodriguez-Yanez M, et al. (2009). Usefulness of haptoglobin and serum amyloid A proteins as biomarkers for atherothrombotic ischemic stroke diagnosis confirmation. Atherosclerosis, 205: 561-567
http://dx.doi.org/10.1016/j.atherosclerosis.2008.12.028
[26] Staals J, Pieters BM, Knottnerus IL, Rouhl RP, van Oostenbrugge RJ, Delanghe JR, et al. (2008). Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res, 5: 153-158
http://dx.doi.org/10.2174/156720208785425675
[27] Wassdal I, Myrset AH, Helgeland L (1991). A simple and rapid method for purification of rat haptoglobin for production of antiserum. Scand J Clin Lab Invest, 51: 565-569
http://dx.doi.org/10.3109/00365519109104566
[28] Ferro JM, Crespo M (1994). Prognosis after transient ischemic attack and ischemic stroke in young adults. Stroke, 25: 1611-1616
http://dx.doi.org/10.1161/01.STR.25.8.1611
[29] Hankey GJ (2013). Stroke in young adults: implications of the long-term prognosis. JAMA, 309: 1171-1172
http://dx.doi.org/10.1001/jama.2013.2319
[30] Varona JF, Bermejo F, Guerra JM, Molina JA (2004). Long-term prognosis of ischemic stroke in young adults. Study of 272 cases. J Neurol, 251: 1507-1514
http://118.145.16.217/magsci/article/article?id=15949821
[31] Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, et al. (2014). Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science, 344: 649-652
http://dx.doi.org/10.1126/science.1251152
[32] Ding J, Kopchick JJ (2011). Plasma biomarkers of mouse aging. Age (Dordr), 33: 291-307
http://dx.doi.org/10.1007/s11357-010-9179-z
[33] Hansson LO, Kjellman NI, Ludvigsson J, Lundh B, Tibbling G (1983). Haptoglobin concentrations in children aged 9-10 years and its correlation to indirect parameters of erythrocyte turnover. Scand J Clin Lab Invest, 43: 367-370
[34] Ratanasopa K, Chakane S, Ilyas M, Nantasenamat C, Bulow L (2013). Trapping of human hemoglobin by haptoglobin: molecular mechanisms and clinical applications. Antioxid Redox Signal, 18: 2364-2374
http://118.145.16.217/magsci/article/article?id=20786905
[35] Chamoun V, Zeman A, Blennow K, Fredman P, Wallin A, Keir G, et al. (2001). Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF. Journal of the neurological sciences, 182: 117-121
http://dx.doi.org/10.1016/S0022-510X(00)00461-5
[36] Johnson G, Brane D, Block W, van Kammen DP, Gurklis J, Peters JL, et al. (1992). Cerebrospinal fluid protein variations in common to Alzheimer’s disease and schizophrenia. Appl Theor Electrophor, 3: 47-53
[37] Arguelles S, Venero JL, Garcia-Rodriguez S, Tomas-Camardiel M, Ayala A, Cano J, et al. (2010). Use of haptoglobin and transthyretin as potential biomarkers for the preclinical diagnosis of Parkinson’s disease. Neurochemistry international, 57: 227-234
http://118.145.16.217/magsci/article/article?id=15271939
[38] Huang YC, Wu YR, Tseng MY, Chen YC, Hsieh SY, Chen CM (2011). Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington’s disease. PLoS One, 6: e15809
http://dx.doi.org/10.1371/journal.pone.0015809
[1] Junfeng Liu,Deren Wang,Yao Xiong,Bian Liu,Jing Lin,Shihong Zhang,Bo Wu,Chenchen Wei,Ming Liu. Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease[J]. A&D, 2017, 8(2): 131-135.
[2] Mohammed Hussain,Neil Datta,Zhe Cheng,David Dornbos,Asif Bashir,Ibrahim Sultan,Tapan Mehta,Faris Shweikeh,Paul Mazaris,Nora Lee,Amre Nouh,Xiaokun Geng,Yuchuan Ding. Spanning from the West to East: An Updated Review on Endovascular Treatment of Intracranial Atherosclerotic Disease[J]. A&D, 2017, 8(2): 196-202.
[3] Rodrigo Ferrari,Sandra C. Fuchs,Luiz Fernando Martins Kruel,Eduardo Lusa Cadore,Cristine Lima Alberton,Ronei Silveira Pinto,Régis Radaelli,Maira Schoenell,Mikel Izquierdo,Hirofumi Tanaka,Daniel Umpierre. Effects of Different Concurrent Resistance and Aerobic Training Frequencies on Muscle Power and Muscle Quality in Trained Elderly Men: A Randomized Clinical Trial[J]. A&D, 2016, 7(6): 697-704.
[4] Qian Li, Yuanshao Lin, Wensi Huang, Yulei Zhou, Xiaoli Chen, Brian Wang, Wanli Zhang, Zhengyi Cai, Jie Xue, Wenhui Zhang, Tieer Yu, Hong Wang, Jincai He, Kunlin Jin, Bei Shao. Serum IL-33 Is a Novel Diagnostic and Prognostic Biomarker in Acute Ischemic Stroke[J]. A&D, 2016, 7(5): 614-622.
[5] Changhong Ren,Ning Li,Brian Wang,Yong Yang,Jinhuan Gao,Sijie Li,Yuchuan Ding,Kunlin Jin,Xunming Ji. Limb Ischemic Perconditioning Attenuates Blood-Brain Barrier Disruption by Inhibiting Activity of MMP-9 and Occludin Degradation after Focal Cerebral Ischemia[J]. A&D, 2015, 6(6): 406-417.
[6] Changhong Ren,Brian Wang,Ning Li,Kunlin Jin,Xunming Ji. Herbal Formula Danggui-Shaoyao-San Promotes Neurogenesis and Angiogenesis in Rat Following Middle Cerebral Artery Occlusion[J]. A&D, 2015, 6(4): 245-253.
[7] Sun Jung Kim,Joo Hun Lee,Boram Han,Julia Lam,Elizabeth Bukowy,Avinash Rao,Jordan Vulcano,Anelia Andreeva,Heather Bertelson,Hyun Phil Shin,Ji Won Yoo. Effects of Hospital-Based Physical Therapy on Hospital Discharge Outcomes among Hospitalized Older Adults with Community-Acquired Pneumonia and DecliningPhysical Function[J]. A&D, 2015, 6(3): 174-179.
[8] Juliane Schulze,Antje Vogelgesang,Alexander Dressel. Catecholamines, Steroids and Immune Alterations in Ischemic Stroke and Other Acute Diseases[J]. Aging and Disease, 2014, 5(5): 327-339.
[9] Eduardo Lusa Cadore,Ronei Silveira Pinto,Martim Bottaro,Mikel Izquierdo. Strength and Endurance Training Prescription in Healthy and Frail Elderly[J]. Aging and Disease, 2014, 5(3): 183-195.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail: editorial@aginganddisease.org
Powered by Beijing Magtech Co. Ltd